Barinthus Biotherapeutics (BRNS) Free Cash Flow (2020 - 2025)
Historic Free Cash Flow for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$10.7 million.
- Barinthus Biotherapeutics' Free Cash Flow rose 4142.64% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.0 million, marking a year-over-year increase of 5012.72%. This contributed to the annual value of -$29.8 million for FY2024, which is 4704.82% up from last year.
- Latest data reveals that Barinthus Biotherapeutics reported Free Cash Flow of -$10.7 million as of Q3 2025, which was up 4142.64% from -$18.1 million recorded in Q2 2025.
- Barinthus Biotherapeutics' Free Cash Flow's 5-year high stood at $12.8 million during Q4 2024, with a 5-year trough of -$20.0 million in Q2 2023.
- In the last 5 years, Barinthus Biotherapeutics' Free Cash Flow had a median value of -$11.2 million in 2023 and averaged -$9.7 million.
- As far as peak fluctuations go, Barinthus Biotherapeutics' Free Cash Flow plummeted by 51112.94% in 2021, and later soared by 54165.89% in 2022.
- Quarter analysis of 5 years shows Barinthus Biotherapeutics' Free Cash Flow stood at -$8.4 million in 2021, then plummeted by 42.08% to -$11.9 million in 2022, then crashed by 63.05% to -$19.4 million in 2023, then surged by 165.85% to $12.8 million in 2024, then tumbled by 183.74% to -$10.7 million in 2025.
- Its Free Cash Flow stands at -$10.7 million for Q3 2025, versus -$18.1 million for Q2 2025 and -$14.9 million for Q1 2025.